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Background: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel strain of 
coronavirus, which is the cause of the current coronavirus disease 2019 (COVID-19) pandemic, ravaging many 
countries of the world. The objective of this study is to assess the symptomatology and case management 
outcome of hospitalized COVID-19 patients in Ondo State, Southwestern Nigeria. 
Methodology: This was a longitudinal study carried out on randomly selected patients with COVID-19, confirmed 
by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR), admitted to the Infectious Disease 
Hospital, Akure, from March to July 2020. Clinical and outcome data obtained from the patients were analysed 
using the Statistical Package for the Social Sciences (SPSS) version 24.0 software, and variables were compared 
using the Chi square (χ²) test and Odds ratio (OR). 
Results: A total of 215 hospitalized COVID-19 patients were randomly recruited, with 103 males and 112 females 
(M:F ratio of 1:1.1), and mean age of 37.24 ± 16.83 years. The most common symptoms were shortness of 
breath (22.8%), cough (18.6%), fatigue (17.2%), runny nose (16.7%), fever (16.3%), and sneezing (14.0%). 
Mortality rate among the patients was 4.7% (10/215). Statistical analysis showed that fever [χ² = 8.75, OR 2.17 
(95% CI: 0.29-16.63), p=0.003] and sneezing [χ²=11.35, OR 2.75 (95% CI: 0.34-18.27), p=0.001] were clinical 
presentations with significant impact on the final outcome of the patients.  
Conclusion: This study showed that the most common symptoms in hospitalized COVID-19 patients were 
shortness of breath, cough, running nose, fever and sneezing, which underscores the importance of monitoring 
of patients for these symptoms. 
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Contexte: Le coronavirus-2 du syndrome respiratoire aigu sévère (SRAS-CoV-2) est une nouvelle souche de 
coronavirus, qui est à l'origine de la pandémie actuelle de coronavirus 2019 (COVID-19), ravageant de nombreux 
pays du monde. L'objectif de cette étude est d'évaluer les résultats de la symptomatologie et de la prise en charge 
des cas de patients hospitalisés COVID-19 dans l'État d'Ondo, dans le sud-ouest du Nigéria.                      




Méthodologie: Il s'agissait d'une étude longitudinale réalisée sur des patients sélectionnés au hasard atteints 
de COVID-19, confirmée par réaction en chaîne par transcriptase-polymérase inverse en temps réel (rRT-PCR), 
admis à l'hôpital des maladies infectieuses d'Akure de mars à juillet 2020. Les données cliniques et les résultats 
obtenus des patients ont été analysés à l'aide du logiciel Statistical Package for the Social Sciences (SPSS) version 
24.0, et les variables ont été comparées à l'aide du test du Chi carré (χ²) et du rapport de cotes (OR).                            
Résultats: Un total de 215 patients hospitalisés COVID-19 ont été recrutés au hasard, avec 103 hommes et 112 
femmes (rapport H: F de 1: 1,1), et un âge moyen de 37,24±16,83 ans. Les symptômes les plus courants étaient 
l'essoufflement (22,8%), la toux (18,6%), la fatigue (17,2%), l'écoulement nasal (16,7%), la fièvre (16,3%) et 
les éternuements (14,0%). Le taux de mortalité parmi les patients était de 4,7% (10/215). L'analyse statistique 
a montré que la fièvre [χ²=8,75, OR 2,17 (IC à 95%: 0,29 à 16,63), p=0,003] et les éternuements [χ²=11,35, 
OR 2,75 (IC à 95%: 0,34 à 18,27), p=0,001] étaient présentations cliniques avec un impact significatif sur le 
résultat final des patients.                                
Conclusion: Cette étude a montré que les symptômes les plus courants chez les patients hospitalisés sous 
COVID-19 étaient l'essoufflement, la toux, le nez qui coule, la fièvre et les éternuements, ce qui souligne 
l'importance de la surveillance des patients pour ces symptômes. 
 




Coronavirus disease 2019 (COVID-19) 
is an infectious disease caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-
CoV-2). It was first identified in Wuhan, the 
capital of Hubei province of China in December 
2019 and has gone on to spread across 
different parts of the world becoming a 
pandemic in the process (1). Specifically, on 
the 29th December, 2019, the first four cases 
of an acute respiratory syndrome of unknown 
aetiology were reported in Wuhan City, Hubei 
Province, China among people linked to a local 
seafood market (2). Studies thus far indicate 
that the virus origin is connected to a seafood 
market in Wuhan, but specific animal associa- 
tions have not been confirmed. Reported sym- 
ptoms include fever, cough, fatigue, head- 
ache, diarrhoea, haemoptysis, and dyspnea. 
Preventive measures such as masks, hand 
hygiene practices, avoidance of public contact, 
and quarantines have been discussed as ways 
to reduce transmission. To date, no specific 
antiviral treatment has proven effective, 
hence, management of infected persons pri- 
marily rely on symptomatic treatment and 
supportive care (3).   
 On 11th March, 2020, the World Health 
Organization (WHO) declared COVID-19 a 
pandemic, having met epidemiological criteria 
of more than a hundred thousand infected 
persons in at least 100 countries (4). The virus 
is primarily spread between people during 
close contact, most often through small drop- 
lets produced by coughing, sneezing, and talk- 
ing. The droplets usually fall to the ground or 
onto surfaces rather than travelling through 
air over long distances (5). While the majority 
of COVID-19 cases have mild symptoms, 
severe complications include acute respiratory 
distress syndrome (ARDs), pneumonia and 
bronchitis (6). These complications are more 
pronounced in patients with underlying health 
conditions such as immuno-compromised indi- 
viduals, the elderly and those with cardio- 
pulmonary diseases (7,8). The time from exp- 
osure to onset of symptoms is typically around 
5 days, but may range from 2-14 days (9,10). 
 The WHO has published several tes- 
ting protocols for the diagnosis of COVID-19 
(11). The standard method of testing is the 
real-time reverse transcription polymerase 
chain reaction (rRT-PCR) (9), which is typic- 
ally done on respiratory samples obtained by 
a nasopharyngeal swab, however, oropharyn- 
geal swab or sputum sample may also be 
used. The samples should be collected after 
48-72 hours of fever subsisting without treat- 
ment (12-15). The treatment of COVID-19 
patients remains largely supportive, with a 
number of cases requiring oxygen supplemen- 
tation and intensive care (16,17). 
The first index case in Nigeria was 
reported on 27th February 2020, when an 
Italian citizen in Lagos tested positive for the 
virus in the wake of increasing cases in Africa 
(18, 19). A second case of the virus was 
reported in Ewekoro, Ogun State on 9th March 
2020 (20), a Nigerian citizen who had been a 
contact of the Italian index case. African 
countries are known to have fragile health 
systems and this remains a source of concern, 
especially in the event of increased outbreaks 
(20). On 23rd March, 2020, Nigeria confirmed 
the first COVID death, a 67-year-old Engineer 
and former managing director of Pipelines and 
Products Marketing Company, who returned 
from United Kingdom with underlying health 
conditions (21). A study on the clinical presen- 
tation of COVID-19 patients in Nigeria by 
Bowale et al., (8), revealed that 75% of the 
patients presented in moderately severe cond- 
ition while 16% were asymptomatic. The most 
common presenting symptoms were fever 
(59%) and dry cough (44%). The study also 
showed that 97% of the patients were treated 
with lopinavir-ritonavir with no recorded death 
while the average duration of hospitalization 
was 12 days (8).    
 In a review of 1556 hospitalized pat- 
ients with COVID-19 (22), 57.5% were male 
and mean age of the patients was 49.1 years. 
Pooled  data  revealed  that  nasal  congestion    
 




was observed in 3.7% of the patients and the 
most common symptoms were fever (85.6%), 
cough (68.7%), and fatigue (39.4%). In a 
South African report on the primary care 
management of COVID-19 patients by Mash 
(23), the common clinical symptoms were 
cough (95%), fever (86%), fatigue (71%), 
shortness of breath (43%) and diarrhoea 
(10%). The severities of the COVID-19 among 
admitted patients in a Chinese study (24) 
were 62% mild, 19% severe, and 19% critical, 
according to the Chinese Center for Disease 
Control (CDC) classification guidelines. The 
patients in the study reportedly received 
standard treatments based on the guidelines 
of Chinese CDC including antiviral remedies 
(arbidol, lopinavir and ritonavir, interferon-α 
inhalation) and anti-inflammatory treatments 
(corticosteroid) among others. Seventeen 
(81%) patients recovered and were dischar- 
ged while 4 (19%) died. In a study of 1591 
Italian patients with SARS-CoV-2 infection, 
patients had clinical manifestations of fever 
(70.1%), cough (45.3%), and expectoration 
(26.7%) at admission (25).   
 There has been several and worryingly 
increasing cases of COVID-19 incidence in the 
study area of the authors and in Nigeria as a 
whole. However, dearth of literature exists on 
the effective management and final outcomes 
of COVID-19. Hence, the objective of this 
study is to assess the clinical presentations 
and outcomes among hospitalized COVID-19 
patients in Ondo State, Southwestern Nigeria.  
Materials and method 
 
Study setting 
 The study was conducted in Ondo 
State, Nigeria, created on February 3, 1976 
from the former Western State with GPS 
coordinates of 7° 6' 0.0180'' N and 4° 50' 
30.0984'' E (Fig 1). It originally included the 
present Ekiti State, which was split off in 
1996. Akure is the State capital and according 
to the 2006 census, the State had a population 
of 3,460,877 (26). 
 
Study design, population and criteria 
 This study was longitudinal in design 
and was conducted on COVID-19 patients 
admitted to the Infectious Disease Hospital, 
Akure, Ondo State from March 2020 to July 
2020. COVID-19 diagnosis was made on the 
basis of positive SARS-COV-2 rRT-PCR test 
(11). Patients whose disease did not require 
hospitalization or for certain reasons were not 
admitted into the hospital, were excluded from 
the study.     
 A simple random sampling method 
was used to select the hospitalized COVID-19 
patients for the study. Data was collected from 
each patient medical record using a chart 
abstraction tool containing biodata, socio-
demographic, clinical presentations, under- 
lying health conditions, management and 
outcome of COVID-19. Ethical approval was 
obtained from the Ondo State Ministry of 





Fig 1: Map of Nigeria showing the location of Ondo State 
  




Specimen collection and laboratory analysis 
 Both oropharyngeal and nasopharyn- 
geal swabs were obtained from each patient 
for the diagnosis of COVID-19 by the real-time 
RT-PCR (rRT-PCR) assay  
 
Statistical analysis 
Clinical data were analysed using the 
Statistical Package for the Social Sciences (SP 
SS) for windows version 24.0 software (SPSS 
Inc; Chicago, IL, USA). Frequency distribution 
was generated for all variables and statistical 
test of significance was performed with Chi-
square test and Odd’s ratio (OR). Other data 
were expressed as mean±standard deviation. 
Significant association was fixed at p<0.05 
and highly significant association at p<0.01. 
 
Results: 
A total of 215 COVID-19 patients were 
studied; 103 males and 112 females (M:F ratio 
of 1:1.1). The mean age of the patients was 
37.24±16.83 years, and over half (53.0%) 
were between the ages 25-44 years (Table 1). 
Tables 2 shows the symptoms exhibited by 
patients. The most common symptoms were 
shortness of breath (22.8%), cough (18.6%), 
fatigue (17.2%), runny nose (16.7%), fever 
(16.3%) and sneezing (14.0%). Less than 2% 
of the patients experienced ageusia and 
anosmia (Tables 2).    
 The patients were routinely treated 
with lopinavir-ritonavir, and also received 
supplements such as vitamin C, zinc and 
calcium. The mean duration of admission was 
9.00±5.20 days, with certain patients admit- 
ted for as long as 39 days. Ten (4.7%) of the 
215 hospitalized patients died and most death 
occurred within 1-3 days of admission. 
 
   
 
Table 1: Age and gender distribution of COVID-19 patients in Ondo State, Nigeria (March – July 2020) 
Age group (years) Gender Total (%) 
Male (%) Female (%) 
<10 
10 – 14 
15 – 19 
20 - 24 
25 – 29 
30 – 34 
35 – 39 
40 – 44 
45 – 49 
50 – 54 






































Total 103 (47.9) 112 (52.1) 215 (100) 
 
 
Table 2: Clinical symptoms in hospitalized COVID-19 patients in Ondo State, Nigeria (March – July 2020) 
Clinical symptom  Frequency (%) 
Fever 
Cough 
































Table 3: Statistical analysis of impacts of clinical symptoms on outcome of hospitalized COVID-19 patients in 
Ondo State, Nigeria (March to July 2020) 
Clinical symptoms *χ² OR 95% CI p value** 
 
























0.04 – 0.51 
 
0.29 – 16.63 
 
0.34 – 18.27 
 









*The null hypothesis is rejected when the Chi square test statistic (χ²) is greater than the critical value of 3.84; **p<0.05 is statistically significant; 
OR = Odds ratio; CI = Confidence interval 
 
Discussion: 
This study revealed that the most 
common symptoms were shortness of breath 
(22.8%), cough (18.6%), fatigue (17.2%), 
runny nose (16.7%), fever (16.3%) and 
sneezing (14.0%). These symptoms are typi- 
cal of the epidemiology of the disease and 
similar to findings of other previous studies in 
Africa, Europe and Asia (8,27,28) although 
COVID-19 has been reported to affect diffe- 
rent people in different ways, with some asy- 
mptomatic for the disease. The most common 
symptoms across the world have been repor- 
ted to include cough and fever (29), thus, this 
study shows that identification of suspected 
COVID-19 patients may be more difficult than 
envisaged as over two-thirds of the patients 
shows neither symptom of cough nor fever. An 
elevated temperature is one way to identify a 
person who may have COVID-19 infection, al- 
though an infected person may be contagious 
without an elevated temperature or not detec- 
ted by the temperature assessment device. 
Therefore, the efficiency of the use of non-
contact temperature assessment devices as 
part of initial check to identify possible COVID-
19 patients may have to be reviewed. This 
suggests that temperature measurements 
alone may not be adequate to identify poten- 
tial positive coronavirus patients.  
This study showed that less than 2% 
of the patients experienced ageusia and anos- 
mia. This is in contrast to a Qatar study which 
reported prevalence rates of ageusia, anos- 
mia, and ageusia and anosmia to be 8.51%, 
11.35%, and 4.96% respectively, with over- 
all prevalence rate 24.8% (30). Loss of smell 
and taste are common complaints in patients 
with the COVID-19, which may present alone 
or with other symptoms. Anosmia has already 
been reported in the course of COVID-19 
worldwide, however, it represents a rare occu- 
rrence as shown in this study. It is not un- 
common for upper respiratory infections to 
affect the senses of smell and taste (31), as 
the sense of taste and sense of smell are 
closely linked. Infact, experiencing a loss of 
smell can greatly impact the sense of taste. It 
is estimated that 95% of the time when there 
is a loss of taste, it is associated with a redu- 
ced sense of smell (31). Therefore, it is not 
uncommon for both to occur together in pati- 
ents as indicated in this study.  
The Chi square and Odd’s ratio (OR) 
showed that fever and sneezing were the two 
clinical symptoms that had impact on the 
outcome of patients. This was evidenced by 
the fact that of the 35 patients who had fever 
on presentation at the point of hospital admis- 
sion, 30 (86%) of them recovered (χ²=8.75, 
OR 2.17, p=0.003), while of 30 patients who 
were sneezing on admission day, 25 (83%) 
recovered from the virus infection (χ²=11.35, 
OR 2.75, p=0.001). Conversely, cough and 
shortness of breath did not have significant 
impact on outcome as 37 (93%) of the 40 
patients who presented with cough at the 
point of hospital admission recovered (χ²= 
0.90, OR 0.51, p=0.343) while 48 of 49 (98%) 
of the patients who presented with shortness 
of breath on the day of admission recovered 
from the disease (χ²=0.98, OR 0.98, p= 
0.323). This observation may be due to the 
fact that most of the COVID-19 patients who 
presented with fever and sneezing had some 
other health conditions (data not shown), 
which may have contributed to these clinical 
symptoms that were further exacerbated by 
the virus infection, thereby impacting the final 
outcome, with more fatalities in this category 




 In conclusion, this study showed that 
the most common clinical presentations in 
COVID-19 include shortness of breath, cough 
and fever, however, identification of suspected 
COVID-19 patients may be more difficult than 
envisaged as over two-thirds of the patients 
showed neither symptom of cough nor fever. 
Temperature measurements alone may not be 
adequate to identify potential positive COVID-
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